Fluvoxamine and chlorimipramine in endogenous depression

Area of Science:

• Pharmacology
• Clinical Medicine
• Psychiatry

Background:

• Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are mainstays in treating various psychiatric conditions.
• Fluvoxamine, an SSRI, and chlorimipramine, a TCA, have demonstrated efficacy, but direct comparative data on their side effect profiles and clinical effectiveness is valuable.

Purpose of the Study:

• To compare the efficacy and safety of fluvoxamine and chlorimipramine in patients.
• To evaluate differences in adverse effects, blood pressure changes, and clinical response between the two antidepressant medications.

Main Methods:

• A randomized, double-blind, controlled study involving thirty patients.
• Patients were treated with either fluvoxamine or chlorimipramine within a dose range of 50-300 mg daily.
• Efficacy was assessed using multiple rating scales, and safety was monitored through blood pressure, ECG, and laboratory variables.

Main Results:

• Fluvoxamine demonstrated superior performance across all efficacy rating scales compared to chlorimipramine, though not statistically significant.
• Chlorimipramine significantly decreased blood pressure, whereas fluvoxamine did not.
• Chlorimipramine was associated with more adverse effects, particularly autonomic symptoms, and required more concurrent anxiolytic medication than fluvoxamine.

Conclusions:

• Fluvoxamine appears to be a more tolerable option with a potentially better efficacy profile than chlorimipramine.
• The findings suggest that fluvoxamine may be preferred when minimizing cardiovascular side effects and autonomic disturbances is a priority.